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Background: Chronic obstructive pulmonary disease (COPD) has been the only leading cause of death associated
with a continuously increasing trend in the US over the past 30 years.
Objectives: The aim of this research was to identify predictors for all-cause in-hospital mortality for COPD patients.
Methods: We conducted a cross-sectional study of patients with the discharge diagnosis of COPD, utilizing the
2007 Premier Perspective database. Inpatients aged 40 years and above were selected if they had a discharge with
a primary diagnosis of COPD between January 1, 2007 and December 31, 2007. All data analyses were based on
individual level. If a patient had multiple discharges, only the last discharge was included for mortality analysis.
Predictors for mortality were identified by multiple logistic regressions. Bonferroni correction for multiple logistic
regression models was adapted to control for family-wise errors.
Results: The total of 57,224 patients was selected for data analysis in the study. All-cause in-hospital mortality for
patients with COPD was 2.4%. Older age, insurance coverage, elective admission, intensive care unit admission,
prolonged length of stay, increased Deyo-adapted Charlson Index (DCI) score and Elixhauser comorbidities of renal
failure, metastatic cancer, solid tumor without metastasis, and weight loss were identified as independent predictors
for all-cause in-hospital mortality. Antibiotics and β-blockers were predictors of lower all-cause in-hospital mortality
risk after adjusting for other factors.
Conclusions: The nationwide discharge database provides useful information to identify predictors for all-cause
in-hospital mortality of patients with COPD.
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Chronic obstructive pulmonary disease (COPD) has
been ranked as the 3rd leading cause of death in the US
only exceeded by heart disease and cancer since 2008
(Minino and Kochanek 2010). A recently released report
on the trends in COPD morbidity and mortality of the US
populations indicated that the number of death caused by
COPD increased from 119,524 in 1999 to 133,965 in 2009
(American Lung Association 2013). It is estimated that
COPD has been the only leading cause of death associated
with a continuously increasing trend in the US over the
past 30 years (COPDGene 2010).* Correspondence: yan.cheng@utah.edu
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in any medium, provided the original work is pSince COPD is a preventable and treatable disease, it is
important to identify the predictors associated with higher
mortality in patients with COPD so that we can take mea-
sures to reduce their risk of death. A review by Steer et al.
discovered that older age, lower diminished forced expira-
tory volume in one second (FEV1), current smoking, prior
hospitalization, poor nutrition status, as well as specific
chronic comobidities were the predictors for both in-
hospital and post-discharge mortality; and acute comorbi-
dites were only independently associated with in-hospital
mortality (Steer et al. 2010). Another recently published
systematic review reported that some specific comorbid
conditions, such as low body mass index (BMI) and cardiac
failure, were significantly associated with both long-term
and short-term in-hospital mortality (Singanayagam et al.
2013). However, there has been a controversy whether a
routinely used comorbidity measure such as the Charlsonn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tients. Previous studies have reported the Charlson Comor-
bidity Index to be a significant predictor of mortality in
COPD patients (Almagro et al. 2002; Casanova et al. 2005;
Casanova et al. 2008; De Torres et al. 2009; Fan et al. 2002;
Marti et al. 2006; Patil et al. 2003), while others did not find
this association (Bustamante-Fermosel et al. 2007; Celli
et al. 2004; Kim et al. 2006; Pinto-Plata et al. 2004; Ranieri
et al. 2008; Soler-Cataluna 2005; Soler-Cataluna et al. 2009;
Terzano et al. 2010). Conversely, the Exlihauser Comorbid-
ity measure, another comorbidity algorithm, is rarely used
to predict mortality risk in patients with COPD.
In this study, we explored the factors associated with all-
cause, in-hospital mortality during COPD related hospital
admissions based on a nationally representative, adminis-
trative hospital discharge database. We assessed: (1) asso-
ciations between mortality and patient socio-demographic
characteristics (i.e., age, race, gender, insurance plan) and
hospital-related characteristics (i.e., hospital location, hos-
pital type, number of beds, admission type, length of stay
(LOS)); (2) association between mortality and patient's
medical characteristics (i.e. Elixhauser comorbidity meas-
ure, Deyo-adapted Charlson Comorbidity Index (DCI), All
Patient Refined Diagnosis Related Groups (APR-DRGa) se-
verity of illness, and APR-DRG risk of mortality); and
(3) relationships between mortality and the use of drug
therapies (β-blockers, oral/parenteral corticosteroids,
and/or antibiotics) during a hospital stay, after adjusting
for other variables.Methods
We utilized the 2007 Premier Perspective database to con-
duct a retrospective, cross-sectional study in patients with
the ICD-9-CM discharge diagnoses of COPD. The Premier
Perspective database and its participants represent a nation-
wide group of hospitals which are willing and have infra-
structure to submit and track the data needed for decisions
about Medicare and Medicaid payments (Premier 2010).
The Premier database used for the study included patient
demographics, insurance status, hospital characteristics,
primary and secondary discharge diagnoses, and pharmaco-
therapy. Inpatient discharges with a primary COPD ICD-9
diagnosis code (491.XX, chronic bronchitis; 492.X, emphy-
sema; or 496, chronic airway obstruction not elsewhere
classified) between January 1, 2007 and December 31, 2007
were selected for this study. We excluded patients younger
than 40 years for the consideration of misclassification of
disease status (American Thoracic Society 1995). Inpatient
discharges missing required any information for the vari-
ables used in the study were also excluded. The analyses
were conducted at the patient level. If a patient had mul-
tiple discharges in the database, only the last discharge
was included.The outcome was all-cause, in-hospital mortality in
COPD patients defined as a dichotomous variable with
values 0 (survived) or 1 (died). Independent variables
included age, gender, race, insurance status, hospital
location, hospital type, number of beds, admission type,
ICU admission, length of stay (LOS), comorbidities
(Elixhauser comorbidities or DCI), APR-DRG severity
of illness, APR-DRG risk of mortality, and pharmaco-
therapy. The pharmacotherapy variable included the use
of β-blockers, oral/parenteral corticosteroids, or antibi-
otics during the hospital stay.
Age was treated as a continuous variable. Race was
categorized as Caucasian, African American, Hispanic,
Asian, American Indian, or other. Insurance status in-
cluded Medicare, Medicaid, managed care, commercial,
other (workers compensation, direct employer contract,
and other government payers), and uninsured. Hospital
location was defined as rural and urban. Hospital type
was defined as teaching and non-teaching. Number of
beds was defined as total number of beds in hospital.
Admission type included emergency, urgent, elective and
trauma. ICU admission was a dichotomous variable, ICU
admission and non-ICU admission. LOS was a count, cal-
culated in days. Comorbid conditions were identified by
the Elixhauser Comorbidity Software, Version 3.1 using
both DRG and ICD-9-CM for each patient per discharge.
The DCI index was based on 17 diagnostic categories
identified from ICD-9-CM discharge diagnoses. Each co-
morbid condition was assigned a weight from the range of
(1,2,3,6). The DCI index was categorized into five groups:
0, 1, 2, 3, 4+. APR-DRG severity of illness was defined as
severity level of each specific DRG, reflecting the extent of
physiologic decompensation or organ system loss of func-
tion and classified into four degrees (minor, moderate,
major, extreme) (Hughes and Development of the 3M™ All
Patient Refined Diagnosis Related Groups APR DRGs
2012) APR-DRG risk of mortality was defined as the likeli-
hood of dying from a specific DRG (minor, moderate,
major and extreme) (Hughes and Development of the 3M™
All Patient Refined Diagnosis Related Groups APR DRGs
2012). Pharmacotherapy included only β-blockers, oral/par-
enteral corticosteroids, and antibiotics because published
literature indicates these are important treatments for
COPD (Rutten et al. 2010; Schols et al. 2001; Fan et al.
2003; Lee et al. 2009; Lee et al. 2008; Dransfield et al. 2008;
Rothberg et al. 2010). Each therapy was created as a dichot-
omous variable with values 0 (not used) and 1 (used).
Collinearity tests and Spearman correlation coeffi-
cients were used to assess the multilinearity between
the independent variables. For each specific DRG, the
outliers of LOS were identified if an observed value for
LOS was larger than the population mean plus 4
standard deviations according to the “68-95-99.7 rule”
(68-95-99.7 rule 2012).
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the association between mortality and each independent
variable, and calculated the odds ratio for each independent
variable by simple logistic regression. A stepwise multiple
logistic regression was conducted to identify significant in-
dependent variables predicting all cause, in-hospital mortal-
ity in COPD patients after adjusting for other covariates.
All statistical analyses were performed using the SAS statis-
tical program, version 9.2 for Windows (SAS Institute,
Cary, NC). For all statistical tests the two sided alpha level
was 0.05. Bonferroni correction was adapted to control the
familywise errors for multiple logistic regression models.
Assuming 20 predictors for outcome death, p values <
0.0025 were considered significant in this analysis.
Results
Characteristics of the studied populations
The 2007 Premier database contained 71,808 discharges
associated with the International Classification of Disease,
Ninth Revision, Clinical Modification (ICD-9-CM) pri-
mary diagnosis of COPD. After we applied inclusion and
exclusion criteria, 69,464 discharges remained, which rep-
resented 57,224 unique individuals. A total of 895 patients
had the last two discharges in the same month, and 65 of
the 895 died in hospital. The remainder of 830 patients
was excluded because it was not possible to determine
which admission was the last in the month. After exclud-
ing those individuals, there were 56,394 unique patients
available for analysis, represented by 86.9% individuals
who had one discharge, 9.5% had two, 2.3% had three, and
1.3% had 4 to 13 discharges in 2007. A total of 1,361 pa-
tients died during hospitalization, thus the all cause, in-
hospital mortality rate in COPD patients was 2.4%. The
mean age was 69.7 (SD 11.7) years, 43.4% were males, and
73.8% were Caucasian. The median LOS was 4 (interquar-
tile range [IQR] 2–6) days.
Among the 56,394 unique patients, 99.83% (n = 56,390)
had non-zero DRG codes and 0.17% (n = 94) had code 0.
For each non-zero DRG code, we calculated the mean and
standard deviation of LOS (Additional file 1). The observa-
tions which had a value for LOS larger than the mean for
that DRG plus 4 times standard deviation were regarded as
outliers and were excluded from the dataset, because these
patients are unique according to Medicare DRG criteria
and could bias the results. The observations with DRG
code 0 were also excluded as the outliers, since there
should have not been the value “0” for DRG code. There-
fore, 427 patients were excluded resulting in 55,967 pa-
tients remaining for the mortality analysis.
The chi-square analyses and t-tests are shown in Table 1.
Patients who died were older than those who survived
with the mean age of 69.6 v.s. 74.4 years. The both groups
had a higher percentage of females than males, but the
proportion of males in patients who died were evenhigher. Compared to patients who survived, patients who
died had a higher proportion of Caucasians and Asians
but a lower proportion of African Americans, Hispanics,
and American Indians. The LOS was longer in patients
who died than patients who survived with the mean value
of 4.7 v.s. 9.0 days. Patients who died had a much higher
proportion of ICU admissions and a higher DCI than
those who survived.
Predictors of in-hospital mortality
After excluding LOS outliers, the bivariate logistic regres-
sions were conducted between mortality and the inde-
pendent variables as shown in Tables 2 and 3. From the
results of the univariate analyses, the mortality risk of pa-
tients of COPD increased by 4% for every increase in age
by 1 year and female patients were 19% less likely to die
compared to male patients. The highest risk of mortality
was in the patients who were Asian (odds ratio [OR] =
1.65; confidence interval [CI] = 1.02-2.65), had other insur-
ance (OR = 3.31; CI = 2.63-4.16), were admitted with elect-
ive admission (OR = 1.95; CI = 1.67-2.27), had extreme
severity of illness (OR = 38.26; CI = 29.61-49.43), had ex-
treme risk of mortality (OR = 88.56; CI = 67.97-115.39),
and were assigned with DCI score of 4 and above (OR =
2.98; CI = 2.50-3.55). Elixhauser comorbidities including
valvular disease (OR = 1.50; CI = 1.07-2.10), other chronic
lung disease (OR = 7.62; CI = 4.53-12.80), renal failure
(OR = 6.39; CI = 3.03-13.46), metastatic cancer (OR = 3.24;
CI = 2.45-4.27), solid tumor without metastasis (OR =
2.10; CI = 1.66-2.67), and weight loss (OR = 5.26; CI =
4.34-6.37) were more likely to happen to patients who
died than who survived; however, comorbid conditions
such as hypothyroidism (OR= 0.82; CI = 0.61-0.98) and de-
pression (OR = 0.68; CI = 0.54-0.85) were associated with
the decreased risk of morality. Oral/parenteral corticoste-
roids (OR = 0.76; CI = 0.66-0.88) and antibiotics (OR = 0.65;
CI = 0.56-0.75) had Odds Ratio less than 1.0, which indi-
cated that they had a protective effect on mortality. How-
ever, β-blockers (OR = 0.99; CI = 0.88-1.10) were not found
to be significantly related to morality.
Since the variables APR-DRG severity of illness, APR-
DRG risk of mortality, and DCI were highly correlated,
we removed the variable APR-DRG severity of illness
and APR-DRG risk of mortality from the multiple logis-
tic regression models. The Spearman correlation coeffi-
cients are displayed in Table 4. All other independent
variables significantly predictive of mortality (p ≤ 0.05) in
the bivariate logistic regressions were retained for multi-
variate analyses.
The multivariate analyses between all cause, in-hospital
mortality for COPD patients and the independent vari-
ables are shown in Table 5. Two models were created for
analysis, because DCI and Elixhauser comorbidities, which
are two algorithms for assessing comorbidities, were






Age (mean ± s.d.) 69.6 ± 11.7 74.4 ± 9.5 <0.001
Gender
Male 23,842 (43.3%) 658 (48.4%) <0.001
Female 31,191 (56.7%) 703 (51.5%)
Race/ethnicity
Caucasian 40,554 (73.7%) 1,035 (76.1%) <0.001
African American 5,356 (9.7%) 104 (7.6%)
Hispanic 1,331 (2.4%) 14 (1.0%)
American Indian 304 (0.6%) 2 (0.2%)
Asian 451 (0.8%) 19 (1.4%)
Other race 7,037 (12.8%) 187 (13.7%)
Insurance type
Medicare 40,130 (72.9%) 1,045 (76.8%) <0.001
Medicaid 4,225 (7.7%) 49 (3.6%)
Managed care 5,742 (10.4%) 82 (6.0%)
Commercial 2,050 (3.7%) 77 (5.7%)
Other 1,056 (1.9%) 86 (6.3%)
Uninsured 1,830 (3.3%) 22 (1.6%)
Hospitals
Urban 46,212 (84.0%) 1,157 (85.0%) 0.301
Rural 8,821 (16.0%) 204 (15.0%)
Teaching 18,722 (34.0%) 467 (34.3%) 0.821
Non-teaching 36,311 (66.0%) 894 (65.7%)
Number of beds (mean ± s.d.) 398.1 ± 222.8 393.7 ± 215.9 0.465
LOS (mean ± s.d.) 4.7 ± 4.1 9.0 ± 9.2 <0.001
Number of discharges
(mean ± s.d.)
1.2 ± 0.6 1.3 ± 0.8 <0.001
Admission type
Emergency 40,555 (73.7%) 906 (66.6%) <0.001
Urgent 9,307 (17.0%) 236 (17.3%)
Elective 4,954 (9.0%) 213 (15.7%)
Trauma 217 (0.4%) 6 (0.4%)
ICU admission 4,521 (8.2%) 600 (44.1%) <0.001
APR-DRG severity of illness
Minor 10,616 (19.3%) 67 (4.9%) <0.001
Moderate 24,659 (44.8%) 218 (16.0%)
Major 17,176 (31.2%) 438 (32.2%)
Extreme 2,582 (4.7%) 638 (46.9%)
APR-DRG risk of mortality
Minor 20,979 (38.1%) 64 (4.7%) <0.001
Moderate 21,900 (39.8%) 301 (22.1%)
Major 10,249 (18.6%) 476 (35.0%)
Extreme 1,905 (3.5%) 520 (38.2%)
Table 1 Description of the studied samples (N = 56,394)
(Continued)
Drug therapies
Oral/parenteral corticosteroids 46,990 (85.4%) 1,116 (82.0%) <0.001
Antibiotics 48,132 (87.5%) 1,122 (82.4%) <0.001
β-blockers 18,143 (33.0%) 448 (32.9%) 0.969
DCI score
0 22,614 (41.1%) 360 (26.5%) <0.001
1 15,013 (27.3%) 373 (27.4%)
2 8,558 (15.6%) 250 (18.4%)
3 4,319 (7.9%) 156 (11.5%)
4+ 4,529 (8.2%) 222 (16.3%)
Elixhauser comorbidity*
Valvular disease 1,027 (1.9%) 36 (2.7%) 0.037
Paralysis 119 (0.22%) 2 (0.2%) 0.803**
Neurological disorders 1,175 (2.1%) 32 (2.4%) 0.586
Other chronic lung disease 97 (0.2%) 17 (1.3%) <0.001
Hypothyroidism 6,969 (12.7%) 143 (10.5%) 0.018
Renal failure 54 (0.1%) 8 (0.6%) <0.001
AIDS 112 (0.2%) 2 (0.2%) 0.878**
Lymphoma 301 (0.6%) 13 (1.0%) 0.047
Metastatic cancer 756 (1.4%) 58 (4.3%) <0.001
Solid tumor w/out metastasis 1,539 (2.8%) 82 (6.0%) <0.001
Rheumatoid arthritis 169 (0.3%) 4 (0.3%) 1.000**
Weight loss 1,140 (2.1%) 139 (10.2%) <0.001
Deficiency anemias 462 (0.8%) 9 (0.7%) 0.475
Psychoses 2,013 (3.7%) 39 (2.9%) 0.123
Depression 5,021 (9.1%) 92 (6.8%) 0.003
*For congestive heart failure, pulmonary circulation disease, peripheral
vascular disease, hypertension, diabetes w/o chronic complications, diabetes
w/ chronic complications, liver disease, peptic ulcer disease bleeding,
coagulopthy, obesity, fluid and electrolyte disorders, chronic blood loss
anemia, alcohol abuse, and drug abuse, no individual was found.
**Yates correction is applied for those violated the assumption that 5 or more
in all cells of a 2-by-2 table.
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Lemeshow tests indicated that both models fit reasonably
well (p = 0.14 in the Elixhauser model; p = 0.23 in the DCI
model). In collinearity tests, we did not find significant
collinearity among the independent variables in each
model. In both models, the mortality risk of patients of
COPD increased by 6% for every 1 year increase in age.
The highest risk of mortality was among patients who
had: Asian race, insurance in the category defined as
“other”, an elective admission, an ICU admission, and DCI
score of 4 and above. The Elixhauser comorbidities of
renal failure, metastatic cancer, solid tumor without me-
tastasis, and weight loss were predictive of mortality; while
comorbid conditions of hypothyroidism and depression
were associated with the decreased risk of morality. Oral/
Table 2 Univariate analysis of in-hospital mortality
(N = 55,967)
Characteristics Unadjusted OR 95% Confidence
interval
P-value
Age (increase by 1 year) 1.04 1.04-1.05 0.003
Gender
Male 1.0 - <0.001
Female 0.81 0.73-0.91
Race/ethnicity
Caucasian 1.0 - <0.001
African American 0.76 0.62-0.94
Hispanic 0.40 0.23-0.69
American Indian 0.27 0.07-1.09
Asian 1.65 1.02-2.65
Other race 1.04 0.88-1.22
Insurance type
Medicare 1.0 - <0.001
Medicaid 0.45 0.34-0.61





Urban 1.0 - 0.187
Rural 0.90 0.77-1.05
Non-teaching 1.0 - 0.621
Teaching 1.03 0.92-1.16
Number of beds 1.0 1.00-1.00 0.503
Admission type




ICU admission 8.82 7.87-9.88 <0.001
DRG severity of illness




DRG risk of mortality




LOS (increase by 1 day) 1.11 1.10-1.12 <0.001
Number of discharges 1.27 1.19-1.35 <0.001
Table 2 Univariate analysis of in-hospital mortality




Antibiotics 0.65 0.56-0.75 <0.001
β-blockers 0.99 0.88-1.10 0.827
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odds ratio less than 1.0, which indicated that they were as-
sociated with lower mortality. Gender was significantly as-
sociated with mortality in the DCI model, but was not
significant in the Elixhauser model. Valvular disease and
other chronic lung diseases that were significant in bivari-
ate analysis were not significant predictors in the multivar-
iable model. However, the use of β-blockers that was not
significant in the bivariate analysis, was associated with
lower mortality risk after adjusting for patient age, gender,
race/ethnicity, insurance type, and comorbidities.
An interaction between insurance type and admission
type was found in both models. After adjusting the inter-
action, we found that the estimates of other independent
variables were similar for each model. To define the source
of the interaction we ran the model by each admission type
(emergency, urgent, elective, and trauma). Among patients
with emergency or trauma admissions, insurance type was
not an independent predictor of in-hospital mortality.
Among patients with urgent admissions, patients in the
“other” insurance category had the highest risk of morality
(Elixhauser model: OR 16.14 95% CI 10.12-25.75; DCI
model: OR 16.44, 95% CI 10.34-26.14), followed by patients
with commercial insurance (Elixhauser model: OR 4.45
95% CI 2.61-7.58; DCI model: OR 4.61, 95% CI 2.72-7.82)
and, then managed care (Elixhauser model: OR 1.95, 95%
CI 1.10-3.43; DCI model: OR 1.88, 95% CI 1.06-3.32).
Among patients with elective admissions, patients in the
“other” insurance category had the highest risk of morality
(Elixhauser model: OR 12.80, 95% CI 7.44-22.04; DCI
model: OR 13.89, 95% CI 8.07-23.93), followed by patients
with commercial insurance (Elixhauser model: OR 7.25,
95% CI 4.38-12.00; DCI model: OR 7.41, 95% CI 4.49-
12.22), no insurance (Elixhauser model: OR 3.83, 95% CI
1.46-10.03; DCI model: OR 4.85, 95% CI 1.92-12.27), and
managed care (Elixhauser model: OR 2.10, 95% CI 1.15-
3.83; DCI model: OR 2.11, 95% CI 1.16-3.85).
In order to control familywise error rates caused by
these multiple comparisons, we used a Bonferroni correc-
tion to get adjusted p-values for independent variables in
each model. After Bonferroni corrections, gender, African
American race, and corticosteroids were not significantly
associated with mortality in the DCI model; and race/eth-
nicity, corticosteroids, and depression were not associated
with mortality any longer in the Elixhauser model.
Table 3 Univariate analysis of in-hospital mortality
(N = 55,967)










No comorbidity 1.0 - -
Valvular disease 1.50 1.07-2.10 0.026
Paralysis 0.71 0.18-2.86 0.607




Hypothyroidism 0.82 0.68-0.98 0.021
Renal failure 6.39 3.03-13.46 <0.001
AIDS 0.38 0.05-2.69 0.247
Lymphoma 1.71 0.96-3.05 0.095




Rheumatoid arthritis 1.00 0.37-2.69 1.000
Weight loss 5.26 4.34-6.37 <0.001
Deficiency anemias 0.65 0.31-1.37 0.218
Psychoses 0.73 0.52-1.03 0.058
Depression 0.68 0.54-0.85 <0.001
*For congestive heart failure, pulmonary circulation disease, peripheral
vascular disease, hypertension, diabetes w/o chronic complications, diabetes
w/ chronic complications, liver disease, peptic ulcer disease bleeding,
coagulopthy, obesity, fluid and electrolyte disorders, chronic blood loss
anemia, alcohol abuse, and drug abuse, no individual was found.
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All-cause, in-hospital mortality in COPD patients was
2.4%; similar to the reported rate of 2.5% based on the
data from the 1996 U.S. Nationwide Inpatient Sample
(Patil et al. 2003). We identified predictors for all-cause in-
hospital mortality in COPD patients from the 2007 Prem-
ier Perspective database. Before this study, we conducted a
literature review of predictors for mortality among patientsTable 4 Spearman correlation test for APR-DRG severity of ill
APR-DRG
APR-DRG* severity of illness Correlation Coefficient
P-value
APR-DRG* risk of mortality Correlation Coefficient
P-value
*APR-DRG: All Patient Refined Diagnosis Related Groups.with COPD and found that previous articles studied pre-
dictors primarily based on physiologic data (Cheng et al.
2011). However, in this study we identified significant pre-
dictors that included patients’ socio-demographic and
medical characteristics, as well as hospital-specific charac-
teristics. Although patient laboratory test results and
physiologic indicators are not included in the Premier
database, our findings may help health care providers iden-
tify COPD patients who would be more likely to die when
admitted to the hospital. In addition, the study has several
other advantages including a large sample size, use of
population-based data, and inclusion of pharmacotherapy
during the hospital stay.
In this study, we explored the ability of both the DCI and
Elixhauser comorbidity measures to predict mortality in
COPD patients. Compared to the DCI, the Elixhauser co-
morbidity measure does not assign a weight for each co-
morbid condition or give a summary score for comorbidity
severity, but allows identification of specific comorbid con-
ditions associated with in-hospital mortality. Although it
was not our purpose to compare the two algorithms for co-
morbidities to predict health outcomes and both Elixhauser
comorbidity measure and the DCI improved the predictive
ability of the models we note the following differences. The
DCI had a dose–response association with increased risk of
in-hospital mortality in this study. The Elixhauser comor-
bidity measure identified specific comorbid conditions asso-
ciated with significantly increased mortality risk; including
renal failure, metastatic cancer, solid tumor without metas-
tasis, and weight loss. COPD patients with hypothyroidism
had significantly lower mortality risk, and this finding was
consistent with some studies that have confirmed that sub-
clinical hypothyroidism was associated with reduced all-
cause mortality (Sathyapalan et al. 2010; Razvi et al. 2008;
Gussekloo et al. 2004). It was reported previously that eld-
erly individuals with higher thyrotropin-stimulating hor-
mone had a longer life expectancy than those with normal
levels (Gussekloo et al. 2004). Our study sample had an
average age of 69.7 years old, so it was not out of expect-
ation to see hypothyroidism had a protective effect on all-
cause mortality of COPD patients. Although the recently
published systematic review identified diabetes mellitus and
congestive heart disease as the predictors of increased mor-
tality in hospitalized COPD patients (Singanayagam et al.
2013), neither was statistically significant in our study.ness, APR-DRG risk of mortality, and DCI





Table 5 Multivariate analyses of all cause, in-hospital mortality of COPD patients (N = 55,967)
Characteristic Elixhauser model* DCI model**









Age (increase by 1 year) 1.06 1.05-1.07 <0.001 0.0060 1.06 1.05-1.07 <0.001 0.0060
Gender
Male - - - 1.0 - 0.029 <0.0001
Female - - 0.88 0.78-0.98
Race/ethnicity
Caucasian 1.0 - 0.005 0.0002 1.0 - 0.003 0.0004
African American 0.79 0.63-0.98 0.78 0.62-0.97
Hispanic 0.43 0.25-0.75 0.41 0.23-0.71
American Indian 0.35 0.09-1.43 0.34 0.08-1.38
Asian 1.29 0.77-2.16 1.27 0.76-2.12
Other race 0.91 0.77-1.08 0.91 0.77-1.08
Insurance type
Medicare 1.0 - <0.001 0.0031 1.0 - <0.001 0.0031
Medicaid 1.12 0.81-1.55 1.11 0.80-1.54
Managed care 1.13 0.88-1.44 1.15 0.90-1.47
Commercial 2.46 1.89-3.20 2.48 1.91-3.23
Other 5.82 4.53-7.49 5.99 4.66-7.70
Uninsured 1.41 0.87-2.24 1.56 0.99-2.48
Admission type
Emergency 1.0 - <0.001 0.0009 1.0 - <0.001 0.0010
Urgent 1.13 0.96-1.32 1.15 0.99-1.35
Elective 1.86 1.57-2.19 1.95 1.65-2.30
Trauma 1.70 0.74-3.92 1.76 0.76-4.05
ICU admission 8.08 7.09-9.20 <0.001 0.0204 7.95 6.99-9.05 <0.001 0.0204
LOS (increase by 1 day) 1.06 1.05-1.07 <0.001 0.0027 1.06 1.05-1.07 <0.001 0.0027
Number of discharges 1.33 1.24-1.42 <0.001 0.0009 1.32 1.23-1.41 <0.001 0.0010
Therapies
β-blockers 0.76 0.67-0.86 0.011 0.0003 0.68 0.60-0.95 <0.001 0.0006
Corticosteroids 0.82 0.70-0.95 <0.001 0.0001 0.82 0.70-0.95 0.010 0.0001
Antibiotics 0.54 0.46-0.63 <0.001 0.0013 0.55 0.47-0.65 <0.001 0.0012
DCI score
0 - - - 1.0 - <0.001 0.0010
1 - - 1.35 1.16-1.58
2 - - 1.46 1.22-1.74
3 - - 1.54 1.25-1.90
4+ - - 2.18 1.80-2.64
Elixhauser comorbidity
Hypothyroidism 0.73 0.61-0.88 0.001 0.0002 - - -
Renal failure 5.12 2.29-11.43 <0.001 0.0003 - - -
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Table 5 Multivariate analyses of all cause, in-hospital mortality of COPD patients (N = 55,967) (Continued)
Metastatic cancer 3.07 2.28-4.13 <0.001 0.0009 - - -
Solid tumor w/out metastasis 1.72 1.33-2.24 <0.001 0.0003 - - -
Weight loss 2.62 2.10-3.26 <0.001 0.0013 - - -
Depression 0.78 0.62-0.98 0.034 0.0001 - - -
*ORs are adjusted for all variables in the table except for DCI scores. The p value for good of fitness Hosmer-Lemeshow test is 0.142, and R-squared value is 0.039.
**ORs are adjusted for all variables in the table except for Elixhauser comorbidities. The p value for good of fitness Hosmer–Lemeshow test is 0.23, and R-squared
value is 0.037.
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sial factor associated with mortality risk in the study. In
the Elixhauser model, gender was not a significant factor
to predict mortality, but in the DCI model, males had sig-
nificantly higher in-hospital mortality risk than females.
This finding was also consistent with COPD mortality
odds ratio of male (OR = 1.17, CI = 1.07-1.27) reported.(5)
However, after making the Bonferroni correction, gender
was no longer a predictor of in-hospital mortality in the
DCI model.
While previous studies have rarely reported race as a
predictor of mortality among COPD patients, our re-
sults showed race-related differences. African Americans
and Hispanics had a significantly lower risk of death than
Caucasians in the both models, but only Hispanics
remained statistically significant after Bonferroni correc-
tion in the DCI model. A review of COPD in Hispanics
had a similar finding; lower mortality rates for COPD
among Hispanics compared to non-Hispanics at each time
point in the study period (Brehm and Celedon 2008). A
recently issued report also confirmed that compared to
non-Hispanic Whites and Blacks, Hispanics had a much
lower age-adjusted death in both male and female patients
with COPD (American Lung Assocation 2013).
Health insurance types were found to be related to
morality risk. Patients with commercial and other insur-
ances (including workers compensation, direct employer
contract, and other government payers) had a signifi-
cantly higher risk for mortality than those with Medicare
or Medicaid. The out-of-pocket expenditure usually may
be greater under commercial insurance than under pub-
lic insurance such as Medicare and Medicare (Ku and
Broaddus 2008). Patients under private insurance might
hesitate to consume healthcare services in the early stage
of disease, therefore hospitalized patients under private
insurance would be more likely have worse health out-
comes than those under public insurance. This explan-
ation could be related to the results of our sub-analyses
by admission type. We found insurance was only associ-
ated with decreased risk of in-hospital mortality among
patients with urgent or elective admissions who had less
severe medical condition than patients with emergency
admissions. Insurance coverage was predictive for the
patients with urgent or elective admission but not for
emergency admissions. Elective admission was found tobe associated with a higher risk of mortality compared
to emergency admission. This was different from what
was found in the previous studies and our hypothesis
that patients admitted from an emergency department
might have higher acuity of disease, placing them at a
higher risk of mortality (Patil et al. 2003). Although the
reason behind the phenomenon is unclear, there would
be several possible explanations. One is that physicians
in emergency room have experience in correctly diag-
nosing disease and appropriately treating patients. Emer-
gency rooms are usually well equipped with medical
professionals and health care resources to resuscitate pa-
tients with COPD exacerbations. As for elective admis-
sion, patients have to wait several days for obtaining
authorization before they receive in-hospital care, so that
COPD severity would get worse when they are admitted.
So, another explanation is that patients who had elective
admission might have more severe COPD than patients
who had emergency admission due to the delayed care.
The third is potentially related to coding and reporting
errors. Since more than 600 hospitals contribute to the
database, there may be inconsistent coding between hospi-
tals .(Premier research service 2010) The study shows that
oral/parenteral corticosteroids, antibiotics, and β-blockers
were associated with decreased mortality risk in the both
models, but after the Bonferroni correction corticosteroids
were no longer associated with mortality risk. Although
patients who were treated with these therapies may have a
more severe disease, these treatments appeared to lower
mortality. Several studies have verified that using antibi-
otics could reduce treatment failure and mortality in pa-
tients with acute exacerbations of COPD and patients
with moderate or severe COPD (Evensen 2010; Stefan
et al. 2013; Roede et al. 2009). Other studies have also
found β-blockers have benefits for reducing mortality of
COPD patients by reducing cardiovascular risk (Short
et al. 2011; Tashkin 2012; Rutten et al. 2010). Since use of
these therapies has shown promising beneficial effects on
survival in COPD patients, prescribing these therapies
should be studied in prospective research and possibly in-
corporated into clinical practice to manage COPD patients
at high risk of mortality.
Several potential limitations were considered. First, the
Premier database and its participants represented only
the nationwide group of hospitals with the willingness
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decisions about Medicare payments (Premier research
service 2010) Thus our study results may have limited
generalizability. Second, we included only the patient’s pri-
mary discharge ICD-9-CM diagnosis if related to COPD.
There could be misclassification of COPD with another
respiratory illness such as asthma or cardiac disease, such
as congestive heart failure. In addition, no spirometric data
or inhaler use information was available in database to
support the diagnosis. However, only including patients
who were at least 40 years old could control misclassifica-
tion of disease status, since misclassification would be
more likely to occur among young patients. Third, some
important predictors of mortality identified in the litera-
ture reviews such as FEV1, dyspnea, arterial blood gas
measure, quality of life, body mass index, exercise toler-
ance, and inflammation were not available in the Premier
database. However, we included other important informa-
tion regarding comorbity such as the DCI and Elixhauser
comorbidities to predict mortality. We also included hos-
pital, admission information and health insurance status,
which were rarely evaluated in previously published stud-
ies. Fourth, APR-DRG severity of illness and APR-DRG
risk of mortality were found to be strong predictors for
mortality in the bivariate analyses, but we did not include
them in the final models in order to obtain comparative
results with previous studies. These were rarely used in
published articles however DCI and comorbid conditions
reflect the severity of disease. Fifth, the data were analyzed
on the last discharge of patients in year 2007. Since this
was a cross-sectional study rather than a longitudinal
study, information from previous years was not available,
for instance, number of hospitalizations in previous years.
Sixth, duration and dosage of each therapy were not avail-
able. Finally, many unobservable factors might bias the
study results, such as smoking status, socioeconomic sta-
tus, and severity of COPD exacerbation.
Conclusion
In a study based on the nationwide discharge database, we
found that older age, commercial and other insurance,
elective admission, ICU admission, extended LOS, in-
creased number of discharges, high DCI score, and Elixhau-
ser comorbidities of renal failure, metastatic cancer, solid
tumor without metastasis and weight loss, were associated
with increased risk of all-cause in-hospital mortality of pa-
tients with COPD. However, antibiotics and β-blockers
were associated with decreased mortality risk. We suggest
that health care providers should consider these factors
when assigning health resources to patients with COPD.
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